0001140361-22-017649.txt : 20220504 0001140361-22-017649.hdr.sgml : 20220504 20220504162212 ACCESSION NUMBER: 0001140361-22-017649 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20220504 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220504 DATE AS OF CHANGE: 20220504 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NU SKIN ENTERPRISES, INC. CENTRAL INDEX KEY: 0001021561 STANDARD INDUSTRIAL CLASSIFICATION: WHOLESALE-DRUGS PROPRIETARIES & DRUGGISTS' SUNDRIES [5122] IRS NUMBER: 870565309 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-12421 FILM NUMBER: 22891830 BUSINESS ADDRESS: STREET 1: 75 WEST CENTER ST STREET 2: ATTN: GREGORY BELLISTON CITY: PROVO STATE: UT ZIP: 84601 BUSINESS PHONE: 801-345-1000 MAIL ADDRESS: STREET 1: 75 WEST CENTER ST STREET 2: ATTN: GREGORY BELLISTON CITY: PROVO STATE: UT ZIP: 84601 FORMER COMPANY: FORMER CONFORMED NAME: NU SKIN ENTERPRISES INC DATE OF NAME CHANGE: 19980909 FORMER COMPANY: FORMER CONFORMED NAME: NU SKIN ASIA PACIFIC INC DATE OF NAME CHANGE: 19960919 8-K 1 brhc10037177_8k.htm FORM 8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 
May 4, 2022
  
 
Date of Report (Date of earliest event reported)
 

 
NU SKIN ENTERPRISES, INC.
  
 
(Exact name of registrant as specified in its charter)
 

Delaware
  
001-12421
  
87-0565309
(State or other jurisdiction of incorporation)
  
(Commission File Number)
 
(IRS Employer Identification Number)

 
75 West Center Street
Provo, Utah 84601
  
 
(Address of principal executive offices and zip code)
 

 
(801) 345-1000
  
 
(Registrant’s telephone number, including area code)
 

 
N/A
  
 
(Former name or former address, if changed since last report)
  

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Class A Common Stock, $.001 par value
 NUS
New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02
Results of Operations and Financial Condition.

On May 4, 2022, Nu Skin Enterprises, Inc. (the “Company”) issued a press release announcing its financial results for the three-month period ended March 31, 2022, and certain other information. A copy of the press release is attached as Exhibit 99.1 to this report.

The information furnished pursuant to this Item 2.02 and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act except as shall be expressly set forth by specific reference in such filing.

Item 9.01
Financial Statements and Exhibits.

(d) Exhibits.

99.1
Nu Skin Enterprises’ press release dated May 4, 2022, regarding financial results for the three-month period ended March 31, 2022.

104
Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
NU SKIN ENTERPRISES, INC.
 
(Registrant)
   
 
/s/ Mark H. Lawrence
  
 
Mark H. Lawrence
 
Chief Financial Officer
Date:  May 4, 2022
  

 
 EX-99.1 2 brhc10037177_ex99-1.htm PRESS RELEASE DATED MAY 4, 2022
Exhibit 99.1


 FOR IMMEDIATE RELEASE

Nu Skin Enterprises Reports First Quarter Financial Results

PROVO, Utah — May 4, 2022 — Nu Skin Enterprises, Inc. (NYSE: NUS) today announced first quarter 2022 results.

Executive Summary
Q1 2022 vs. Prior-year Quarter

Revenue:

$604.9 million; (11)%
•    (3)% FX impact or $(17.2) million
Earnings Per Share (EPS):

$0.76; (16)%
Customers:

1,321,451; (13)%
Paid Affiliates:

251,436; (14)%
Sales Leaders:

52,462; (22)%

“Despite heightened global uncertainty and COVID-related obstacles, we are pleased with our first quarter results, which exceeded guidance,” said Ryan Napierski, Nu Skin president and CEO. “Demand remained strong for our most recent product introductions, ageLOC® Meta and Beauty Focus™ Collagen+, and the momentum from these product launches helped drive strong revenue growth in several markets including the U.S., Taiwan and Southeast Asia. Our business in Mainland China and several other markets was disrupted due to severe COVID-related lockdowns and other factors, and the conflict in Ukraine and Russia negatively impacted business throughout the EMEA region.

“As we look ahead to the remainder of the year, we are focused on the strategic imperatives that underpin Nu Vision 2025, including: EmpowerMe, our personalized beauty and wellness strategy with connected beauty device introductions beginning in the third quarter; expansion of our affiliate-powered social commerce business model; and the continued enhancement of our digital platform. While we anticipate near-term headwinds given the dynamic macro environment, we remain confident in the significant growth potential of our business, achieving our vision for the future and driving value for our shareholders.”

Nu Skin Enterprises Reports First Quarter Financial Results
page 2
Q1 2022 Year-over-year Operating Results

Revenue:

$604.9 million compared to $677.0 million
•    (3)% FX impact
Gross Margin:

73.3% compared to 74.8%
•    Impacted by product mix and promotions
•    Nu Skin business was 76.5% compared to 77.8%
Selling Expenses:

40.1% compared to 40.8%
•    Nu Skin business was 43.0% compared to 43.7%
G&A Expenses:

24.6% compared to 24.8%
Operating Margin:

8.6% compared to 9.3%
Other Income / (Expense):

$(1.5) million compared to $1.6 million
Income Tax Rate:

23.6% compared to 26.5%
EPS:

$0.76 compared to $0.91

Stockholder Value

Dividend Payments:

$19.3 million
Stock Repurchases:

$10.0 million
•    $235.4 million remaining in authorization

Q2 and Full-year 2022 Outlook

Q2 2022 Revenue:

$590 to $620 million; (16) to (12)%
•    Approximately (3) to (4)% FX impact
Q2 2022 EPS:

$0.75 to $0.85; (35) to (26)%
2022 Revenue:

$2.51 to $2.62 billion; (7) to (3)%
•    Approximately (3) to (4)% FX impact
2022 EPS:

$3.60 to $3.90; 26 to 36% on a reported basis, or (13) to (6)% non-GAAP

“Our results outperformed expectations in the first quarter including a beat in revenue and earnings per share driven in part by sales late in the quarter ahead of an April 1 price increase,” added Mark Lawrence, chief financial officer. “In light of the ongoing global uncertainties, including increasing COVID-related factors, foreign exchange pressure and geopolitical conflict, we are adjusting our annual guidance. Our 2022 revenue guidance is $2.51 to $2.62 billion with a 3 to 4 percent foreign currency headwind and EPS of $3.60 to $3.90. We are projecting second quarter revenue of $590 to $620 million with a 3 to 4 percent foreign currency headwind and EPS of $0.75 to $0.85.”
 
Nu Skin Enterprises Reports First Quarter Financial Results
page 3
Conference Call
The Nu Skin Enterprises management team will host a conference call with the investment community today at 5 p.m. (ET). Those wishing to access the webcast, as well as the financial information presented during the call, can visit the Investor Relations page on the company’s website at ir.nuskin.com. A replay of the webcast will be available on the same page through May 18, 2022.
 
About Nu Skin Enterprises, Inc.
Nu Skin Enterprises, Inc. (NYSE: NUS) is a leading beauty and wellness company, powered by a dynamic affiliate opportunity platform. The company helps people look, feel and live their best with products that combine the best of science, technology and nature. Backed by more than 35 years of scientific research, Nu Skin develops innovative products including Nu Skin® personal care, Pharmanex® nutrition and the ageLOC® anti-aging brand which includes an award-winning line of beauty device systems. Nu Skin operates in approximately 50 markets worldwide in the Americas, Asia, Europe, Africa and the Pacific. Rhyz Inc. is the company’s strategic investment arm that includes a collection of technology and manufacturing companies to support growth in the core Nu Skin business. Nu Skin is committed to sustainability, including global initiatives such as transitioning to reduced and sustainable packaging for all products by 2030. The Nu Skin Force for Good Foundation also strives to improve children’s health, education and economic circumstances throughout the world. For more information, visit nuskin.com.
 
Important Information Regarding Forward-Looking Statements: This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that represent the company’s current expectations and beliefs. All statements other than statements of historical fact are “forward-looking statements” for purposes of federal and state securities laws and include, but are not limited to, statements of management’s expectations regarding the company’s performance, growth, shareholder value, strategies, vision, transformation, initiatives, product pipeline and product introductions, digital and social-commerce tools and initiatives, customers, sales leaders and affiliates; operational improvements, projections regarding revenue, expenses, operating income, earnings per share, foreign currency fluctuations, uses of cash and other financial items; statements of belief; and statements of assumptions underlying any of the foregoing. In some cases, you can identify these statements by forward-looking words such as “believe,” “expect,” “anticipate,” “project,” “outlook,” “guidance,” “remain,” “become,” “plan,” “opportunity,” “expand,” “will,” “would,” “could,” “may,” “might,” the negative of these words and other similar words.

Nu Skin Enterprises Reports First Quarter Financial Results
page 4
The forward-looking statements and related assumptions involve risks and uncertainties that could cause actual results and outcomes to differ materially from any forward-looking statements or views expressed herein. These risks and uncertainties include, but are not limited to, the following:


 •
risk that epidemics, including the ongoing COVID-19 pandemic, and other crises could negatively impact our business;

•
adverse publicity related to the company’s business, products, industry or any legal actions or complaints by the company’s sales force or others;

•
risk that direct selling laws and regulations in any of the company’s markets, including the United States and Mainland China, may be modified, interpreted or enforced in a manner that results in negative changes to the company’s business model or negatively impacts its revenue, sales force or business, including through the interruption of sales activities, loss of licenses, increased scrutiny of sales force actions, imposition of fines, or any other adverse actions or events;

•
any failure of current or planned initiatives or products to generate interest among the company’s sales force and customers and generate sponsoring and selling activities on a sustained basis;

•
political, legal, tax and regulatory uncertainties associated with operating in international markets, including Mainland China;

•
uncertainty regarding meeting restrictions and other government scrutiny in Mainland China, as well as negative media and consumer sentiment in Mainland China on our business operations and results;

•
risk of foreign-currency fluctuations and the currency translation impact on the company’s business associated with these fluctuations;

•
uncertainties regarding the future financial performance of the businesses the company has acquired;

•
risks related to accurately predicting, delivering or maintaining sufficient quantities of products to support planned initiatives or launch strategies, and increased risk of inventory write-offs if the company over-forecasts demand for a product or changes its planned initiatives or launch strategies;

•
regulatory risks associated with the company’s products, which could require the company to modify its claims or inhibit its ability to import or continue selling a product in a market if the product is determined to be a medical device or if the company is unable to register the product in a timely manner under applicable regulatory requirements;

•
unpredictable economic conditions and events globally, including trade policies and tariffs;

•
the company’s future tax-planning initiatives; any prospective or retrospective increases in duties on the company’s products imported into the company’s markets outside of the United States; and any adverse results of tax audits or unfavorable changes to tax laws in the company’s various markets; and

•
continued competitive pressures in the company’s markets.
 
The company’s financial performance and the forward-looking statements contained herein are further qualified by a detailed discussion of associated risks set forth in the documents filed by the company with the Securities and Exchange Commission. The forward-looking statements set forth the company’s beliefs as of the date that such information was first provided, and the company assumes no duty to update the forward-looking statements contained in this release to reflect any change except as required by law.

Non-GAAP Financial Measures: Constant-currency revenue change is a non-GAAP financial measure that removes the impact of fluctuations in foreign-currency exchange rates, thereby facilitating period-to-period comparisons of the company’s performance. It is calculated by translating the current period’s revenue at the same average exchange rates in effect during the applicable prior-year period and then comparing that amount to the prior-year period’s revenue. The company believes that constant-currency revenue change is useful to investors, lenders and analysts because such information enables them to gauge the impact of foreign-currency fluctuations on the company’s revenue from period to period.

Earnings per share and adjusted earnings per share growth, each excluding impairment and restructuring charges, also are non-GAAP financial measures. Impairment and restructuring charges are not part of the ongoing operations of our underlying business. The company believes that these non-GAAP financial measures are useful to investors, lenders and analysts because removing the impact of impairment and restructuring charges facilitates period-to-period comparisons of the company’s performance. Please see the reconciliations of these items to our earnings per share and earnings per share growth calculated under GAAP, below.

Nu Skin Enterprises Reports First Quarter Financial Results
page 5
The following table sets forth revenue for the three-month periods ended March 31, 2022 and 2021 for each of our reportable segments (U.S. dollars in thousands):

   
Three Months Ended
March 31,
          
Constant-
Currency
  
   
2022
    
2021
    
Change
    
Change
  
Nu Skin
                        
Mainland China
  
$
124,495
    
$
149,593
      
(17
)%
    
(18
)%
Americas
    
123,580
      
133,761
      
(8
)%
    
(6
)%
Southeast Asia/Pacific
    
90,236
      
83,289
      
8
%
    
11
%
South Korea
    
72,133
      
81,131
      
(11
)%
    
(4
)%
Japan
    
61,791
      
69,864
      
(12
)%
    
(3
)%
EMEA
    
52,968
      
76,180
      
(30
)%
    
(25
)%
Hong Kong/Taiwan
    
38,494
      
36,345
      
6
%
    
6
%
Other
    
620
      
878
      
(29
)%
    
(29
)%
Total Nu Skin
    
564,317
      
631,041
      
(11
)%
    
(8
)%
Rhyz Investments
                                
Manufacturing
    
40,341
      
45,985
      
(12
)%
    
(12
)%
Rhyz other
    
241
      
—
                  
Total Rhyz Investments
    
40,582
      
45,985
      
(12
)%
    
(12
)%
Total
  
$
604,899
    
$
677,026
      
(11
)%
    
(8
)%

Nu Skin Enterprises Reports First Quarter Financial Results
page 6
The following table provides information concerning the number of Customers, Paid Affiliates and Sales Leaders in our core Nu Skin business for the three-month periods ended March 31, 2022 and 2021:

   
Three Months Ended
March 31,
        
Customers
  
2022
    
2021
    
Change
  
Mainland China
  
$
289,060
      
316,000
      
(9
)%
Americas
    
318,458
      
374,867
      
(15
)%
Southeast Asia/Pacific
    
165,657
      
185,435
      
(11
)%
South Korea
    
140,648
      
152,390
      
(8
)%
Japan
    
122,616
      
126,525
      
(3
)%
EMEA
    
216,037
      
296,001
      
(27
)%
Hong Kong/Taiwan
    
68,975
      
66,042
      
4
%
Total
    
1,321,451
      
1,517,260
      
(13
)%

   
Three Months Ended
March 31,
        
Paid Affiliates
  
2022
    
2021
    
Change
  
Mainland China
  
$
22,762
      
41,944
      
(46
)%
Americas
    
46,281
      
52,767
      
(12
)%
Southeast Asia/Pacific
    
43,262
      
45,871
      
(6
)%
South Korea
    
49,328
      
51,006
      
(3
)%
Japan
    
38,059
      
38,283
      
(1
)%
EMEA
    
33,834
      
43,696
      
(23
)%
Hong Kong/Taiwan
    
17,910
      
17,885
      
—
  
Total
    
251,436
      
291,452
      
(14
)%

   
Three Months Ended
March 31,
        
 Sales Leaders
  
2022
    
2021
    
Change
  
Mainland China
  
$
14,146
      
23,013
      
(39
)%
Americas
    
9,547
      
11,394
      
(16
)%
Southeast Asia/Pacific
    
8,012
      
8,446
      
(5
)%
South Korea
    
6,072
      
6,682
      
(9
)%
Japan
    
5,977
      
6,135
      
(3
)%
EMEA
    
5,455
      
7,479
      
(27
)%
Hong Kong/Taiwan
    
3,253
      
3,755
      
(13
)%
Total
    
52,462
      
66,904
      
(22
)%

“Customers” are persons who have purchased directly from the Company during the three months ended as of the date indicated. Our Customer numbers include members of our sales force who made such a purchase, including Paid Affiliates and those who qualify as Sales Leaders, but they do not include consumers who purchase products directly from members of our sales force.

“Paid Affiliates” are any Brand Affiliates, as well as sales employees and independent marketers in Mainland China, who earned sales compensation during the three-month period. In all of our markets besides Mainland China, we refer to members of our independent sales force as “Brand Affiliates” because their primary role is to promote our brand and products through their personal social networks.

“Sales Leaders” are the three-month average of our monthly Brand Affiliates, as well as sales employees and independent marketers in Mainland China, who had achieved certain qualification requirements as of the end of each month of the quarter.

Nu Skin Enterprises Reports First Quarter Financial Results
page 7
NU SKIN ENTERPRISES, INC.
Consolidated Statements of Income (Unaudited)
(U.S. dollars in thousands, except per share amounts)

   
Three Months Ended
March 31,
  
   
2022
    
2021
  
Revenue
  
$
604,899
    
$
677,026
  
Cost of sales
    
161,499
      
170,566
  
Gross profit
    
443,400
      
506,460
  
                 
Operating expenses:
                
Selling expenses
    
242,699
      
275,965
  
General and administrative expenses
    
148,556
      
167,582
  
Total operating expenses
    
391,255
      
443,547
  
                 
Operating income
    
52,145
      
62,913
  
Other income (expense), net
    
(1,453
)
    
1,582
  
                 
Income before provision for income taxes
    
50,692
      
64,495
  
Provision for income taxes
    
11,976
      
17,065
  
                 
Net income
  
$
38,716
    
$
47,430
  
                 
Net income per share:
                
Basic
  
$
0.77
    
$
0.94
  
Diluted
  
$
0.76
    
$
0.91
  
                 
Weighted-average common shares outstanding (000s):
                
Basic
    
49,991
      
50,706
  
Diluted
    
51,066
      
52,172
  

Nu Skin Enterprises Reports First Quarter Financial Results
page 8
NU SKIN ENTERPRISES, INC.
Consolidated Balance Sheets (Unaudited)
(U.S. dollars in thousands)

   
March 31,
2022
    
December 31, 2021
  
ASSETS
            
Current assets:
            
Cash and cash equivalents
  
$
302,216
    
$
339,593
  
Current investments
    
15,313
      
15,221
  
Accounts receivable, net
    
52,171
      
41,299
  
Inventories, net
    
381,585
      
399,931
  
Prepaid expenses and other
    
97,923
      
76,906
  
Total current assets
    
849,208
      
872,950
  
                 
Property and equipment, net
    
448,822
      
453,674
  
Operating lease right-of-use assets
    
132,949
      
120,973
  
Goodwill
    
206,432
      
206,432
  
Other intangible assets, net
    
74,874
      
76,991
  
Other assets
    
179,964
      
175,460
  
Total assets
  
$
1,892,249
    
$
1,906,480
  
                 
LIABILITIES AND STOCKHOLDERS’ EQUITY
                
Current liabilities:
                
Accounts payable
  
$
40,719
    
$
49,993
  
Accrued expenses
    
343,737
      
372,201
  
Current portion of long-term debt
    
110,000
      
107,500
  
Total current liabilities
    
494,456
      
529,694
  
                 
Operating lease liabilities
    
100,844
      
88,759
  
Long-term debt
    
258,995
      
268,781
  
Other liabilities
    
103,754
      
106,474
  
Total liabilities
    
958,049
      
993,708
  
                 
Commitments and contingencies
                
                 
Stockholders’ equity:
                
Class A common stock – 500 million shares authorized, $0.001 par value, 90.6 million shares issued
    
91
      
91
  
Additional paid-in capital
    
599,258
      
601,703
  
Treasury stock, at cost – 40.4 million and 40.7 million shares
    
(1,526,778
)
    
(1,526,860
)
Accumulated other comprehensive loss
    
(69,528
)
    
(73,896
)
Retained earnings
    
1,931,157
      
1,911,734
  
Total stockholders’ equity
    
934,200
      
912,772
  
Total liabilities and stockholders’ equity
  
$
1,892,249
    
$
1,906,480
  

Nu Skin Enterprises Reports First Quarter Financial Results
page 9
NU SKIN ENTERPRISES, INC.
Reconciliation of Earnings Per Share Excluding Impact of Restructuring and Impairment to GAAP Earnings Per Share
(in thousands, except per share amounts)

   
Year Ended
2021
    
2022 EPS
Guidance
– low end
    
2022
Projected
Annual
Growth
Rate – low
end
    
2022 EPS
Guidance –
high end
    
2022
Projected
Annual
Growth
Rate – high
end
  
Net income
  
$
147,266
                          
Impact of restructuring and impairment:
                                
Restructuring and impairment
    
51,870
                          
Inventory write-off
    
6,656
                          
Income tax impact
    
6,933
                          
Adjusted net income
  
$
212,725
                          
Diluted earnings per share
  
$
2.86
    
$
3.60
      
26
%
  
$
3.90
      
36
%
Diluted earnings per share, excluding restructuring and impairment impact
  
$
4.14
    
$
3.60
      
(13
%)
  
$
3.90
      
(6
%)
Weighted-average common shares outstanding (000s):
    
51,427
                                  

# # #

CONTACTS:
Media: media@nuskin.com, (801) 345-6397
Investors: investorrelations@nuskin.com, (801) 345-3577


 EX-101.SCH 3 nus-20220504.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 nus-20220504_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Amendment Flag Document Fiscal Year Focus Document Fiscal Period Focus Document Period End Date Entity Registrant Name Entity Central Index Key Entity File Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Emerging Growth Company Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name EX-101.PRE 5 nus-20220504_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 image1.jpg begin 644 image1.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Document and Entity Information
May 04, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 04, 2022
Entity Registrant Name NU SKIN ENTERPRISES, INC.
Entity Incorporation, State or Country Code DE
Entity File Number 001-12421
Entity Tax Identification Number 87-0565309
Entity Address, Address Line One 75 West Center Street
Entity Address, City or Town Provo
Entity Address, State or Province UT
Entity Address, Postal Zip Code 84601
City Area Code 801
Local Phone Number 345-1000
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Entity Central Index Key 0001021561
Title of 12(b) Security Class A Common Stock, $.001 par value
Trading Symbol NUS
Security Exchange Name NYSE
XML 8 brhc10037177_8k_htm.xml IDEA: XBRL DOCUMENT 0001021561 2022-05-04 2022-05-04 false 0001021561 8-K 2022-05-04 NU SKIN ENTERPRISES, INC. DE 001-12421 87-0565309 75 West Center Street Provo UT 84601 801 345-1000 false false false false Class A Common Stock, $.001 par value NUS NYSE false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 1 22 1 false 0 0 false 0 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://nuskin.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports brhc10037177_8k.htm brhc10037177_ex99-1.htm nus-20220504.xsd nus-20220504_lab.xml nus-20220504_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "brhc10037177_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "brhc10037177_8k.htm" ] }, "labelLink": { "local": [ "nus-20220504_lab.xml" ] }, "presentationLink": { "local": [ "nus-20220504_pre.xml" ] }, "schema": { "local": [ "nus-20220504.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2004/ref-2004-08-10.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" ] } }, "elementCount": 29, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "nus", "nsuri": "http://nuskin.com/20220504", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "brhc10037177_8k.htm", "contextRef": "c20220504to20220504", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000100 - Document - Document and Entity Information", "role": "http://nuskin.com/role/DocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "brhc10037177_8k.htm", "contextRef": "c20220504to20220504", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 15 0001140361-22-017649-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001140361-22-017649-xbrl.zip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end